Oncopeptides Fights Latest FDA Attempt to Revoke Pepaxto Approval

Oncopeptides is appealing a formal request from the FDA to withdraw its blood cancer therapy drug Pepaxto (melphalan flufenamide) as the agency flexes its newfound regulatory authority for pulling drugs that receive an accelerated approval but fail confirmatory studies.
Source: Drug Industry Daily